Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators
Retrieved on:
Thursday, April 22, 2021
b'Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, debuted today with a EUR 20 million (approx.
Key Points:
- b'Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, debuted today with a EUR 20 million (approx.
- Anavo\xe2\x80\x99s mission is to pioneer systematic drug discovery and development approaches aimed at phosphatases, a rich and largely untapped therapeutic target class.
- We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators.
- In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.